Investors - Press Releases
|View printer-friendly version|
Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published
In the study, TRHC’s PPRDI first utilized TRHC’s MedWise™ technology to determine each patient’s MedWise Risk Score™ (MRS), which is a predictive tool for adverse drug events (ADEs). Next, five repurposed COVID-19 drugs (or drug combinations) were added, one at a time, to patient drug regimens. The drug combinations included hydroxychloroquine, alone and in combination with azithromycin; chloroquine, alone and in combination with azithromycin; and lopinavir + ritonavir.
“The results of this study validate the science behind our MedWise technology,” states TRHC Chair and CEO
The study showed an increased MRS for a significant number of participants with all drugs (or drug combinations) due to drug-drug interactions competing for their metabolic pathway and the increased risk for drug-induced Long QT syndrome. Long QT syndrome is a disorder that can cause fast and chaotic heartbeats, triggering a sudden fainting spell, seizure, and in some cases, death.
“Our study confirms there is a safe way to examine the risks of adding new medications to an individual’s medication regimen, before they are prescribed the drug,” states TRHC’S PPRDI Chief Operating Officer
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.
TRHC’s PPRDI is committed to developing proprietary products, validation, and recognition by scientific and regulatory communities, improving patient outcomes, and reducing preventable healthcare utilization and costs. In 2020, the TRHC research pillar has 39 active research projects, 32 peer-reviewed publications in well-renowned journals, eight manuscripts accepted for publication, and two
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. These forward-looking statements include, among other things, our goals and expectations regarding the combined company and the integration of PW into TRHC, the expected synergies from the combined company and the expected financial and operating performance of TRHC following the completion of the acquisition. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the risk that we may not be able to achieve our expectations for the combined companies due to challenges in integration and inability to retain key employees; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations and pharmacies; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in our filings with the
|TRHC Media Contact
T: (856) 912-5714
T: (215) 870-0829
T: (312) 451-2157
An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39f266a5-2e22-4c29-8ae7-d2d4d0ce75c4
Source: Tabula Rasa HealthCare, Inc.